Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 19;11(20):3294. doi: 10.3390/cells11203294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Role of ubiquitin specific protease (USP) 7 on the acquired chemoresistance of triple-negative breast cancer (TNBC). (A) Analysis of the viability of MDA-MB-231 cells with transient expression of USP7, USP12, and USP21, respectively, under serial doses of doxorubicin (left panel) or paclitaxel (right panel) treatment, as assed using MTT assays. (B) Protein levels of USP7, USP12, and USP21 in MDA-MB-231 cells with transient expression of USP7, USP12, and USP21, respectively, as assessed using western blot analysis. (C) Analysis of growth ability of MDA-MB-231 cells with transient expression of USP7 treated with doxorubicin (left panel) or paclitaxel (right panel) using colony formation assays. (D) Quantitative analysis of colony formation assays for doxorubicin (left panel) or paclitaxel (right panel)-treated MDA-MB-231-USP7 cells. (E) Analysis of apoptosis in MDA-MB-231 with transient expression of USP7, USP12, and USP21, respectively, treated with doxorubicin (left panel) or paclitaxel (right panel) according to Annexin V-dependent flow cytometry assays. (F) Quantitative analysis of the apoptotic levels of two different doses of doxorubicin (upper panel)- or paclitaxel (lower panel)-treated MDA-MB-231 cells with transient expression of USP7, USP12, or USP21, respectively. Data are represented as the mean ± SEM for biological triplicate experiments. * p < 0.05, compared with the results for control cells.

Role of ubiquitin specific protease (USP) 7 on the acquired chemoresistance of triple-negative breast cancer (TNBC). (A) Analysis of the viability of MDA-MB-231 cells with transient expression of USP7, USP12, and USP21, respectively, under serial doses of doxorubicin (left panel) or paclitaxel (right panel) treatment, as assed using MTT assays. (B) Protein levels of USP7, USP12, and USP21 in MDA-MB-231 cells with transient expression of USP7, USP12, and USP21, respectively, as assessed using western blot analysis. (C) Analysis of growth ability of MDA-MB-231 cells with transient expression of USP7 treated with doxorubicin (left panel) or paclitaxel (right panel) using colony formation assays. (D) Quantitative analysis of colony formation assays for doxorubicin (left panel) or paclitaxel (right panel)-treated MDA-MB-231-USP7 cells. (E) Analysis of apoptosis in MDA-MB-231 with transient expression of USP7, USP12, and USP21, respectively, treated with doxorubicin (left panel) or paclitaxel (right panel) according to Annexin V-dependent flow cytometry assays. (F) Quantitative analysis of the apoptotic levels of two different doses of doxorubicin (upper panel)- or paclitaxel (lower panel)-treated MDA-MB-231 cells with transient expression of USP7, USP12, or USP21, respectively. Data are represented as the mean ± SEM for biological triplicate experiments. * p < 0.05, compared with the results for control cells.